ImageneBio (IMA) Return on Capital Employed (2021 - 2025)
ImageneBio (IMA) posted Return on Capital Employed of 52.47% for Q3 2025, down 41.61% sequentially from 37.05% in Q2 2025, and down 1219.0% YoY from 4.69% in Q3 2024.
ImageneBio (IMA) Return on Capital Employed (2021 - 2025) Analysis & Trends
ImageneBio has reported Return on Capital Employed for 5 years, with the latest figure at 52.47% in Q3 2025.
- Quarterly Return on Capital Employed fell 1219.0% year-over-year to 52.47% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 52.47% (down 1219.0% YoY) and the FY2024 annual result came in at 67.94%, down 2304.0% from the prior year.
- Return on Capital Employed declined to 52.47% in Q3 2025 per IMA's latest filing, from 37.05% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 15.0% in Q4 2021 and troughed at 98.4% in Q4 2024.
- A 5-year average of 40.99% and a median of 39.8% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 5860 bps in 2024, then soared 1103 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 15.0% in 2021, then slumped by 196 bps to 44.35% in 2022, then gained by 10 bps to 39.8% in 2023, then slumped by 147 bps to 98.4% in 2024, then jumped by 47 bps to 52.47% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 52.47%, 37.05%, and 80.46% for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | ImageneBio | 48.60 Mn | -86.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -52.47% |
| Jun 30, 2025 | -37.05% |
| Mar 31, 2025 | -80.46% |
| Dec 31, 2024 | -98.40% |
| Sep 30, 2024 | -40.27% |
| Jun 30, 2024 | -48.08% |
| Mar 31, 2024 | -45.35% |
| Dec 31, 2023 | -39.80% |
| Sep 30, 2023 | -39.37% |
| Jun 30, 2023 | -44.64% |
| Mar 31, 2023 | -46.81% |
| Dec 31, 2022 | -44.35% |
| Sep 30, 2022 | -30.15% |
| Jun 30, 2022 | -26.00% |
| Mar 31, 2022 | -19.47% |
| Dec 31, 2021 | -15.00% |
| Sep 30, 2021 | -26.28% |
| Jun 30, 2021 | -21.39% |
| Mar 31, 2021 | -23.41% |